Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.
Rituxan (rituximab) is a chimeric mAb against CD20 that is approved for the treatment of moderate to severe active RA. It was co-developed by Biogen Idec and Genentech (now a wholly-owned subsidiary of Roche), and is currently marketed by Roche, as well as by Shanghai Henlius Biotech in China. Outside the US, rituximab is marketed by Roche under the brand name MabThera.
- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Rituxan/Mabthera including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Rituxan/Mabthera for the top 9 countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Australia, China and India.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Rituxan/Mabthera performance.
- Obtain sales forecast for Rituxan/Mabthera from 2013-2023 in top 9 countries (the US, France, Germany, Italy, Spain, the UK, Australia, China and India).